TNFSF10 and cancer: More importantly, EV‐T induces significant apoptosis in TRAIL‐resistant cancer cells, indicating that EV‐TRAIL can replace rTRAIL for cancer treatment to obtain better therapeutic effects.[258] The combination of EV‐T with other drug such as SCH727965 (dinaciclib), an effective CDK inhibitor, has been tested in sensitizing the pathway response of cancer cells.